Recent News

• 06.10.2025 - Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
• 06.10.2025 - Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
• 06.05.2025 - Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
• 06.05.2025 - Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
• 05.22.2025 - Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
• 05.22.2025 - Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
• 05.21.2025 - Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
• 05.21.2025 - Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
• 05.14.2025 - Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations
• 05.14.2025 - Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

Recent Filings

• 05.30.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 05.21.2025 - 8-K Current report
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities